Medical/Pharmaceuticals
Smartee and Shanghai Ninth People's Hospital Win First Prize at Shanghai Science and Technology Progress Awards
SHANGHAI, Sept. 10, 2025 /PRNewswire/ -- Smartee Denti-Technology, a global innovator in invisible orthodontic solutions, together with Shanghai Ninth People's Hospital affiliated with Shanghai Jiao Tong University School of Medicine, has been awarded the First Prize of the Shanghai Science and ...
2025-09-12 10:03
1541
The New Drug Application for KN026 (Anbenitamab Injection) Has Been Accepted by the National Medical Products Administration
SUZHOU, China, Sept. 12, 2025 /PRNewswire/ -- Alphamab Oncology (Stock Code: 9966.HK) announced that the New Drug Application (NDA) for anbenitamab injection (KN026), independently developed by the Company and co-developed with JMT-Bio Technology Co., Ltd., a wholly-owned subsidiary of CSPC Pharm...
2025-09-12 09:51
1528
Psoriatic Disease To Take Center Stage at the UN General Assembly: IFPA Calls for Greater Recognition of Psoriatic Disease During UN High-Level Meetings
STOCKHOLM, Sept. 12, 2025 /PRNewswire/ -- The International Federation of Psoriasis Associations (IFPA) spotlights psoriatic disease at the upcoming UNGA 80 inNew York, where world leaders are expected to adopt a new Political Declaration on noncommunicable diseases (NCDs), mental health and well...
2025-09-12 00:16
1993
Zhimeng Biopharma's Investigational Drug Approved to Initiate Phase 2 Epilepsy Clinical Trial in China
SHANGHAI, Sept. 11, 2025 /PRNewswire/ -- Shanghai Zhimeng Biopharma, Inc. ("Zhimeng Biopharma") announced that its self-developed novel next-generation KCNQ2/3 potassium channel opener, CB03-154, has recently received clinical trial approval from the Center for Drug Evaluation (CDE) ofChina's Nat...
2025-09-12 00:00
1756
Datasea Secures Landmark Agreement for First Acoustic Wearable Technology Contract, Marking Entry into the $1 Trillion Market
Driving the Commercialization of Acoustic Technology in Smart Health Wearables through Solution-Based Service Delivery BEIJING, Sept. 11, 2025 /PRNewswire/ -- Datasea Inc. (NASDAQ: DTSS), a Nevada -based technology company specializing in acoustic high-tech products and AI multimodal digital solu...
2025-09-11 21:30
2319
GLOBAL FIRST "High-Definition Image": Decoding the "Code of Youth" - LivingPhoenix's POGMENT Collagen Breakthrough Fills Global Gap
CHENGDU, China, Sept. 11, 2025 /PRNewswire/ -- Recently, LivingPhoenix®Regenerative Technologies Development (Chengdu) Co., Ltd. (hereinafter "LivingPhoenix Technology") announced that its independently developed POGMENT triple-helix biomimetic collagen has, for the first time in the world, achi...
2025-09-11 21:27
1991
Lunit Awarded Major National Tender in France, Expanding Access to Breast AI in Public Hospitals
Framework agreement with UniHA enables access to Lunit's breast AI solutions across 1,500+ French public hospitals, in collaboration with Fujifilm SEOUL, South Korea, Sept. 11, 2025 /PRNewswire/ -- Lunit (KRX:328130.KQ), a leading provider of AI for cancer diagnostics and therapeutics, today anno...
2025-09-11 21:00
1918
YolTech Therapeutics Raises $45 Million in Series B Financing Led by AstraZeneca-CICC
SHANGHAI, Sept. 11, 2025 /PRNewswire/ -- YolTech Therapeutics, a clinical-stage biotech company pioneering in vivo genome editing therapies, today announced the closing of its approximately$45 million Series B financing led by the AstraZeneca-CICC healthcare investment fund. The proceeds will sup...
2025-09-11 20:05
1770
Kazia Therapeutics Reports Complete Ex Vivo Disruption of Large Circulating Tumor Cell Clusters in Stage IV HER2-Positive Breast Cancer with Paxalisib Monotherapy
SYDNEY, Sept. 11, 2025 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA), an oncology-focused drug development company, today announced new findings from a collaborative research program led by ProfessorSudha Rao at QIMR Berghofer. In this ex vivo study, blood samples from Stage IV HER2-...
2025-09-11 20:00
2953
Lundbeck showcases new clinical migraine data, including long-term preventive effectiveness of Vyepti® (eptinezumab) in patients severely impacted by migraine
* Lundbeck demonstrates leadership and unwavering commitment to advancing migraine management and supporting patient outcomes with six presentations at the 2025 International Headache Congress (IHC), including three oral presentations on eptinezumab (Vypeti®) and Lu AG09222 (anti-PACAP mAb) *...
2025-09-11 14:56
1366
HaemaLogiX wins "Most Promising CAR-T Pipeline in APAC" at the Asia Pacific CGT¹ Excellence Awards 2025
SYDNEY, Sept. 11, 2025 /PRNewswire/ -- HaemaLogiX Ltd, a clinical stage Australian biotech, developing novel immunotherapies for patients with blood cancers and B-cell diseases, was honoured to be awarded the"Most Promising CAR-T Pipeline in APAC" at the Asia Pacific CGT Excellence Awards 2025, h...
2025-09-11 11:52
1733
Amaran Biotech Wins Asia-Pacific Biologics CDMO Excellence Award for "Best Fill-Finish"
50-Person Team Demonstrates Taiwan's Biotech Strength HSINCHU, Sept. 11, 2025 /PRNewswire/ -- Amaran Biotech, a next-generation Contract Development and Manufacturing Organization (CDMO), was awarded the "Best Fill-Finish" at the 2025 Asia-Pacific Biologics CDMO Excellence Awards held inSingapore...
2025-09-11 10:00
2074
Fosun International Recognized among Fortune's 2025 "Most Admired Chinese Companies" List
HONG KONG, Sept. 11, 2025 /PRNewswire/ -- On 9 September, Fortune China magazine released its 2025 list of "Most Admired Chinese Companies", in which Fosun International Limited ("Fosun International" or the "Company") (HKEX stock code: 00656) was included in the Industry Star List. This highligh...
2025-09-11 09:00
2846
XingImaging in partnership with SynuSight was awarded a grant from The Michael J. Fox Foundation to support development of the α-synuclein PET tracer 18F-FD4 for Parkinson's disease
NEW HAVEN, Conn., Sept. 11, 2025 /PRNewswire/ -- XingImaging in partnership with SynuSight Biotech has received funding of$3.84M from The Michael J. Fox Foundation to conduct studies on18F-FD4, a specific α-synuclein (α-syn)-targeted PET tracer. Based on prior investigator-initiated trials, the ...
2025-09-11 05:06
993
TVM Capital Healthcare Announces First Closing of its USD 150 Million Southeast Asia Fund
SINGAPORE, Sept. 11, 2025 /PRNewswire/ -- TVM Capital Healthcare, a global private equity investor and operator specialized in healthcare growth capital across emerging markets, today announced the first closing of itsUSD 150 million TVM Healthcare Southeast Asia Fund ("SEA Fund"). The SEA Fund ...
2025-09-11 02:39
2193
Shineco Achieves Mass Production of High-Purity Physical Phospholipids, Breaking Foreign Monopoly and Unlocking Innovation Across Industries
BEIJING, Sept. 10, 2025 /PRNewswire/ -- Shineco Inc. (NASDAQ: SISI) ("Shineco" or the "Company"), a leading developer of induced pluripotent stem cell (iPSC) technology platforms, today announced that its subsidiary, Fuzhou Meidashan Biotechnology Co., Ltd., has successfully achieved large-scale ...
2025-09-10 21:30
1156
C-Ray Therapeutics Supports Mednovo's Phase III Clinical Trial with First Patient Dosed for Lutetium [177Lu] Oxodotreotide Injection
CHENGDU, China, Sept. 10, 2025 /PRNewswire/ -- August 22, 2025, Mednovo Group Co., Ltd. ("Mednovo") announced that the first patient has been successfully dosed in its Phase III clinical trial of Lutetium [177Lu] Oxodotreotide Injection, a Class 3 targeted radiotherapeutic drug. As the exclusive...
2025-09-10 21:30
1090
Imaging Endpoints Announces Patent Application for AI Review Charter System
SCOTTSDALE, Ariz., Sept. 10, 2025 /PRNewswire/ -- Imaging Endpoints (IE), the global leader in Imaging CRO technologies and services for oncology trials, announced the filing of a provisional patent application for its revolutionary AI enhanced Imaging Review Charter (IRC) system. This innovative...
2025-09-10 21:00
1017
LakeShore Biopharma Announces Appointment of Independent Financial Advisor and Legal Counsel to the Special Committee
BEIJING, Sept. 10, 2025 /PRNewswire/ -- LakeShore Biopharma Co., Ltd (Nasdaq: LSB, "LakeShore Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious ...
2025-09-10 20:10
1205
Optain Health Closes $26 Million Series A to Bring Oculomics to Primary Care and Beyond
Insight Partners leads; seven major U.S. health systems join. Funding accelerates the global rollout of Optain's advanced robotic retinal imaging, AI, and teleophthalmology platform. NEW YORK, Sept. 10, 2025 /PRNewswire/ -- Optain Health, a healthcare technology company applying artificial intel...
2025-09-10 20:00
1883
Week's Top Stories
Most Reposted
One Universal Production Group (OUP) Officially Opens, Reinforcing Its Position as Asia's Leading IP Ecosystem and Tourism Company
[Picked up by 313 media titles]
2025-12-20 09:36
Singapore Airshow 2026 Marks 10th Edition with New Frontiers in Aviation and Space
[Picked up by 308 media titles]
2025-12-18 19:41
foodpanda Strengthens Merchant Care with Record Onboarding Milestone in Asia
[Picked up by 292 media titles]
2025-12-18 17:15Synvo AI and Sobat Bisnis Group (SBG) Forge Strategic Partnership to Bring Secure, Context-Aware Enterprise AI to Indonesia and Southeast Asia
[Picked up by 291 media titles]
2025-12-16 08:00
Rosewood Hotel Group Accelerates Global Expansion with On-Track 2025 Openings; Entering New Sector with Its First-Ever Ski Resort
[Picked up by 287 media titles]
2025-12-19 14:40
